Mallinckrodt files NDA for heart agent

Article

Radiopharmaceutical supplierMallinckrodt Medical is taking the jump into technetium-basedcardiac scintigraphy. The St. Louis-based company said last weekthat it has filed a new drug application (NDA) with the Food andDrug Administration for TechneScan

Radiopharmaceutical supplierMallinckrodt Medical is taking the jump into technetium-basedcardiac scintigraphy. The St. Louis-based company said last weekthat it has filed a new drug application (NDA) with the Food andDrug Administration for TechneScan Q12, a technetium-99m agentfor myocardial perfusion imaging.

Mallinckrodt claims that TechneScan Q12 clears more rapidlyfrom the liver than other agents, reducing the level of hepaticuptake that can interfere with cardiac imaging. This may allownuclear medicine physicians to conduct cardiac imaging proceduresmore quickly by reducing the time between injection and imaging,according to the company.

Clinical studies with TechneScan Q12 also indicate that theagent is retained in the myocardium for extended periods of time,prolonging the availability of clear images.

Mallinckrodt's entry into the market for technetium-based cardiacradiopharmaceuticals will increase the number of competitors challengingDu Pont Merck, which has experienced strong market acceptancefor its Cardiolite agent since the product's introduction in 1991(SCAN 1/16/91). Another company vying for Cardiolite's marketshare is Amersham/Medi-Physics, which is waiting for FDA clearancefor Myoview, also a technetium-based agent.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.